Panion & Bf Biotech Inc. (1760.TW)
TWD 66.3
(3.11%)
TWD 66.3
(3.11%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.23 Billion TWD | 4.58% |
| 2022 | 3.09 Billion TWD | 4.76% |
| 2021 | 2.95 Billion TWD | -3.93% |
| 2020 | 3.07 Billion TWD | 60.73% |
| 2019 | 1.91 Billion TWD | 4.23% |
| 2018 | 1.83 Billion TWD | 47.1% |
| 2017 | 1.24 Billion TWD | 4.71% |
| 2016 | 1.19 Billion TWD | 1.35% |
| 2015 | 1.17 Billion TWD | 6.08% |
| 2014 | 1.1 Billion TWD | 10.74% |
| 2013 | 1 Billion TWD | 8.26% |
| 2012 | 924.2 Million TWD | -1.06% |
| 2011 | 934.09 Million TWD | 8.4% |
| 2010 | 861.72 Million TWD | -1.34% |
| 2009 | 873.43 Million TWD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 3.25 Billion TWD | 2.34% |
| 2024 Q1 | 3.17 Billion TWD | -1.82% |
| 2023 FY | 3.23 Billion TWD | 4.58% |
| 2023 Q4 | 3.23 Billion TWD | 5.08% |
| 2023 Q1 | 3.04 Billion TWD | -1.42% |
| 2023 Q3 | 3.07 Billion TWD | -5.14% |
| 2023 Q2 | 3.24 Billion TWD | 6.43% |
| 2022 Q2 | 3.18 Billion TWD | 7.09% |
| 2022 Q4 | 3.09 Billion TWD | -4.95% |
| 2022 Q1 | 2.97 Billion TWD | 0.74% |
| 2022 FY | 3.09 Billion TWD | 4.76% |
| 2022 Q3 | 3.25 Billion TWD | 2.17% |
| 2021 Q2 | 2.96 Billion TWD | -3.6% |
| 2021 Q3 | 3.01 Billion TWD | 1.66% |
| 2021 Q4 | 2.95 Billion TWD | -2.01% |
| 2021 FY | 2.95 Billion TWD | -3.93% |
| 2021 Q1 | 3.07 Billion TWD | 0.03% |
| 2020 Q3 | 1.89 Billion TWD | -1.95% |
| 2020 Q2 | 1.92 Billion TWD | 0.64% |
| 2020 Q1 | 1.91 Billion TWD | 0.24% |
| 2020 Q4 | 3.07 Billion TWD | 62.49% |
| 2020 FY | 3.07 Billion TWD | 60.73% |
| 2019 Q2 | 1.89 Billion TWD | -0.84% |
| 2019 FY | 1.91 Billion TWD | 4.23% |
| 2019 Q3 | 1.75 Billion TWD | -7.71% |
| 2019 Q4 | 1.91 Billion TWD | 9.08% |
| 2019 Q1 | 1.91 Billion TWD | 4.42% |
| 2018 Q3 | 1.7 Billion TWD | -3.45% |
| 2018 FY | 1.83 Billion TWD | 47.1% |
| 2018 Q4 | 1.83 Billion TWD | 7.53% |
| 2018 Q2 | 1.76 Billion TWD | 5.0% |
| 2018 Q1 | 1.68 Billion TWD | 34.93% |
| 2017 Q4 | 1.24 Billion TWD | 2.55% |
| 2017 FY | 1.24 Billion TWD | 4.71% |
| 2017 Q3 | 1.21 Billion TWD | -0.29% |
| 2017 Q2 | 1.21 Billion TWD | 0.0% |
| 2017 Q1 | - TWD | -100.0% |
| 2016 Q1 | 1.09 Billion TWD | -6.81% |
| 2016 Q2 | 1.09 Billion TWD | 0.0% |
| 2016 Q4 | 1.19 Billion TWD | 0.0% |
| 2016 FY | 1.19 Billion TWD | 1.35% |
| 2015 Q1 | 1.14 Billion TWD | 3.74% |
| 2015 FY | 1.17 Billion TWD | 6.08% |
| 2015 Q2 | 1.14 Billion TWD | 0.0% |
| 2015 Q4 | 1.17 Billion TWD | 0.0% |
| 2015 Q3 | 1.17 Billion TWD | 2.26% |
| 2014 Q1 | 1.05 Billion TWD | 5.47% |
| 2014 Q2 | 1.05 Billion TWD | 0.0% |
| 2014 FY | 1.1 Billion TWD | 10.74% |
| 2014 Q4 | 1.1 Billion TWD | 0.0% |
| 2014 Q3 | 1.1 Billion TWD | 5.0% |
| 2013 Q1 | 956.24 Million TWD | 3.47% |
| 2013 Q2 | 956.24 Million TWD | 0.0% |
| 2013 Q3 | 1 Billion TWD | 4.63% |
| 2013 Q4 | 1 Billion TWD | 0.0% |
| 2013 FY | 1 Billion TWD | 8.26% |
| 2012 Q2 | 916.01 Million TWD | 0.0% |
| 2012 Q3 | 924.03 Million TWD | 0.88% |
| 2012 FY | 924.2 Million TWD | -1.06% |
| 2012 Q4 | 924.2 Million TWD | 0.02% |
| 2011 Q2 | 865.87 Million TWD | 0.0% |
| 2011 FY | 934.09 Million TWD | 8.4% |
| 2011 Q4 | 934.09 Million TWD | 0.0% |
| 2010 Q4 | 861.72 Million TWD | 0.0% |
| 2010 FY | 861.72 Million TWD | -1.34% |
| 2009 FY | 873.43 Million TWD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Apex Biotechnology Corp. | 2.29 Billion TWD | -40.844% |
| Sinphar Pharmaceutical Co.,Ltd. | 6.25 Billion TWD | 48.246% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 5.17 Billion TWD | 37.444% |
| GenMont Biotech Incorporation | 1.65 Billion TWD | -95.694% |
| Abnova (Taiwan) Corporation | 1.35 Billion TWD | -138.628% |
| Adimmune Corporation | 9.48 Billion TWD | 65.89% |
| Tanvex BioPharma, Inc. | 2.76 Billion TWD | -17.072% |
| Polaris Group | 9.09 Billion TWD | 64.441% |
| Energenesis Biomedical CO.,LTD. | 828.57 Million TWD | -290.454% |
| UnicoCell Biomed Co., Ltd. | 685.92 Million TWD | -371.65% |
| PELL Bio-Med Technology Co. Ltd. | 1.41 Billion TWD | -128.126% |